Twitter Beğeni Hilesi

Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity. bit.ly/3Tb11a7

mTOR Signaling Promotes Rapid m6A mRNA Methylation to Regulate NK-Cell Activation and Effector Functions. bit.ly/3SNI90A

Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway. bit.ly/4dMZsHd

Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade. bit.ly/3YOGw6G

New Johns Hopkins Medicine study in Cancer Immunology Research reveals CCR6 is key in Treg-induced immunosuppression. Targeting CCR6 boosts CD8 T cell activity & enhances checkpoint inhibitors, offering a new strategy for resistant tumors like GBM #CancerResearch #Immunotherapy bit.ly/3X87Gnu

Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells. bit.ly/3XiYD2j

Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade—don't miss this review by Natalija Budimir et al., featured in the AACR Journals Collection on Immunotherapy. bit.ly/3yKKdzI

Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy. bit.ly/3X0zkSj

#ICYMI: The August issue of Cancer Immunology Research is online now. bit.ly/3T6QJI1 #CancerImmunology

ICYMI: CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity. bit.ly/4dX1owI Cullinan Therapeutics

#ICYMI: In the August issue: CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity. bit.ly/3z08AcH Cullinan Therapeutics

#ICYMI: T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer. bit.ly/4dZ3H2n

#ICYMI: Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. bit.ly/3Tb0gNY

Learn more: bit.ly/3T9A7zo #openaccess

Get to know the 2024 AACR Journal Award winners, read their impactful articles, and tune in for their interviews to learn more about their work. bit.ly/3X9rWnw

#ICYMI: Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. bit.ly/4cQjfEv

August Editors’ Picks from the 10 AACR journals include a “colon-age” metric for personalizing colorectal cancer screening, a look at how violent environments affect stress signaling in lung tumors, and more. Learn more on the #AACRBlog: bit.ly/3XsWRge

Check out the AACR journal articles published concurrently with presentations during #AACR24. bit.ly/3ZuA5Gj

Checkout our paired Perspective and Priority Brief in Cancer Immunology Research! Amazing collab with Carl June, Joseph Fraietta and Saar Gill that we hope will help researchers, product developers and regulators advance gene edited T cell therapies. aacrjournals.org/cancerimmunolr…